[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR20C1043I1 - Vaccins avec adjuvants dotés d'antigènes non virioniques préparés à partir de virus de la grippe cultivés dans une culture cellulaire - Google Patents

Vaccins avec adjuvants dotés d'antigènes non virioniques préparés à partir de virus de la grippe cultivés dans une culture cellulaire

Info

Publication number
FR20C1043I1
FR20C1043I1 FR20C1043C FR20C1043C FR20C1043I1 FR 20C1043 I1 FR20C1043 I1 FR 20C1043I1 FR 20C1043 C FR20C1043 C FR 20C1043C FR 20C1043 C FR20C1043 C FR 20C1043C FR 20C1043 I1 FR20C1043 I1 FR 20C1043I1
Authority
FR
France
Prior art keywords
vironic
growed
cell culture
influenza viruses
antigens prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR20C1043C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seqirus UK Ltd
Original Assignee
Seqirus UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seqirus UK Ltd filed Critical Seqirus UK Ltd
Publication of FR20C1043I1 publication Critical patent/FR20C1043I1/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
FR20C1043C 2005-11-04 2020-09-01 Vaccins avec adjuvants dotés d'antigènes non virioniques préparés à partir de virus de la grippe cultivés dans une culture cellulaire Active FR20C1043I1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73402605P 2005-11-04 2005-11-04
US73565805P 2005-11-11 2005-11-11
EP06808424.3A EP1945252B1 (de) 2005-11-04 2006-11-06 Squalen adjuvans-impfstoff influenza oberflächen-antigene gereinigt aus in zellkulturen gezüchteten influenza-viren enthaltend
PCT/GB2006/004128 WO2007052055A1 (en) 2005-11-04 2006-11-06 Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture

Publications (1)

Publication Number Publication Date
FR20C1043I1 true FR20C1043I1 (fr) 2020-10-16

Family

ID=37831416

Family Applications (1)

Application Number Title Priority Date Filing Date
FR20C1043C Active FR20C1043I1 (fr) 2005-11-04 2020-09-01 Vaccins avec adjuvants dotés d'antigènes non virioniques préparés à partir de virus de la grippe cultivés dans une culture cellulaire

Country Status (15)

Country Link
US (2) US10842867B2 (de)
EP (3) EP2368572B1 (de)
JP (1) JP2009514838A (de)
AU (1) AU2006310336B2 (de)
CA (1) CA2628152C (de)
DK (1) DK2368572T3 (de)
ES (2) ES2792398T3 (de)
FI (1) FIC20240033I1 (de)
FR (1) FR20C1043I1 (de)
HK (1) HK1122997A1 (de)
HU (1) HUE051122T2 (de)
NZ (1) NZ567981A (de)
PL (2) PL2368572T3 (de)
PT (1) PT2368572T (de)
WO (1) WO2007052055A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2525572T3 (es) * 2006-07-17 2014-12-26 Glaxosmithkline Biologicals S.A. Vacuna antigripal
EA200900024A1 (ru) 2006-07-17 2009-06-30 Глаксосмитклайн Байолоджикалс С.А. Противогриппозная вакцина
AR066405A1 (es) 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa Vacuna
AU2020228151A1 (en) 2019-02-25 2021-10-21 Seqirus UK Limited Adjuvanted multivalent influenza vaccines
MX2022005513A (es) 2019-11-07 2022-06-08 Seqirus Uk Ltd Composiciones y metodos para producir una vacuna viral con tama?o de particula reducido.

Family Cites Families (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4060082A (en) 1976-08-16 1977-11-29 Mpl, Inc. Dual-ingredient medication dispenser
US4500513A (en) 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
JPS62201573A (ja) 1986-02-27 1987-09-05 Shionogi & Co Ltd 家禽用インフルエンザワクチン
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ230423A (en) 1988-08-25 1993-08-26 Liposome Co Inc A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
CA2017507C (en) * 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
DK0582581T3 (da) 1991-03-01 1999-11-08 Minnesota Mining & Mfg 1,2-substituerede 1H-imidazo[4,5-c]quinolin-4-aminer
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JPH0614756Y2 (ja) 1991-06-26 1994-04-20 株式会社アルテ 組み立て式の２室式容器兼用注射器
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5750110A (en) 1992-06-25 1998-05-12 Smithkline Beecham Biologicals, S.A Vaccine composition containing adjuvants
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
ATE157882T1 (de) 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
DE69425661T2 (de) 1993-07-15 2001-04-19 Minnesota Mining And Mfg. Co., St. Paul IMIDAZO [4,5-c]PYRIDIN-4-AMINE
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
ES2370937T3 (es) 1993-09-13 2011-12-23 Protein Sciences Corporation Un método para producir vacunas antigripales polivalentes a base de hemaglutinina.
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US5496284A (en) 1994-09-27 1996-03-05 Waldenburg; Ottfried Dual-chamber syringe & method
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
DK0791055T3 (da) 1994-11-10 2012-04-16 Baxter Healthcare Sa Fremgangsmåde til fremstilling af biologiske produkter i proteinfri kultur
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
GB9503863D0 (en) 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) * 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
AU3186297A (en) 1996-07-05 1998-02-02 Debiotech S.A. Dual-chamber syringe for mixing two substances prior to injection
DE69733020T2 (de) 1996-10-11 2006-02-16 The Regents Of The University Of California, Oakland Immunostimulierende oligonucleotidekonjugate
AT405939B (de) 1997-02-24 1999-12-27 Immuno Ag Verfahren zur inaktivierung von lipidumhüllten viren
EP2172216A3 (de) 1997-03-10 2010-11-24 Ottawa Hospital Research Institute Verwendung von Nukleinsäuren, die unmethylierte CPG-Dinukleotide enthalten als Adjuvantien
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
WO1998046262A1 (en) 1997-04-16 1998-10-22 Connaught Laboratories, Inc. Anti-influenza compositions supplemented with neuraminidase
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US5971953A (en) 1998-01-09 1999-10-26 Bachynsky; Nicholas Dual chamber syringe apparatus
AU9785598A (en) 1997-10-03 1999-04-27 Texas Pharmaceuticals, Inc. Improved dual chamber syringe apparatus
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
WO1999027961A1 (en) 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
US6782510B1 (en) 1998-01-27 2004-08-24 John N. Gross Word checking tool for controlling the language content in documents using dictionaries with modifyable status fields
AU746163B2 (en) 1998-04-09 2002-04-18 Smithkline Beecham Biologicals (Sa) Adjuvant compositions
DK1075276T3 (da) 1998-05-07 2008-02-11 Corixa Corp Adjuvanssammensætning og fremgangsmåder til dens anvendelse
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE19835749C1 (de) 1998-08-07 2000-02-03 Dieter Perthes Fertig-Spritze für nicht-stabile Arzneimittel
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
DE122007000087I1 (de) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
PT1150918E (pt) 1999-02-03 2005-01-31 Biosante Pharmaceuticals Inc Metodo de fabrico de particulas terapeuticas de fosfato de calcio
WO2000050006A2 (en) * 1999-02-26 2000-08-31 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
EP1955709B1 (de) 1999-03-26 2012-03-14 Vical Incorporated Adjuvanzverbindungen zur Verbesserung von Immunreaktionen auf Polynukleotid-basierten Impfstoffen
WO2000060050A2 (en) 1999-04-06 2000-10-12 Wisconsin Alumni Research Foundation Recombinant influenza viruses for vaccines and gene therapy
HU229255B1 (en) * 1999-04-19 2013-10-28 Smithkline Beecham Biolog Vaccines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
DK1194580T4 (da) * 1999-07-14 2011-01-03 Sinai School Medicine In-vitro rekonstitution af segmenterede negativstrengede RNA-virus
BR0014285A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
CO5280082A1 (es) 1999-09-24 2003-05-30 Smithkline Beecham Corp Nueva vacuna
PL355163A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
CN101543507A (zh) 1999-09-25 2009-09-30 衣阿华大学研究基金会 免疫刺激性核酸
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20040109874A1 (en) 1999-11-10 2004-06-10 Powderject Vaccines, Inc. Induction of mucosal immunity by vaccination via the skin route
AU3108001A (en) 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
JP4698112B2 (ja) 2000-03-03 2011-06-08 一般財団法人化学及血清療法研究所 無血清培養かつ浮遊培養可能な細胞及び当該細胞を用いたワクチン用ウイルスの製造法
EP1276468A1 (de) 2000-04-26 2003-01-22 Biovector Therapeutics S.A. Verwendung teilchenförmiger vektoren in der immunomodulation
EP1317559B1 (de) 2000-04-28 2009-01-07 St. Jude Children's Research Hospital Dna-transfektionssystem zur erzeugung von infektiösen negativsträngigen rna virus
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
ATE448226T1 (de) 2000-09-01 2009-11-15 Novartis Vaccines & Diagnostic Aza heterocyclische derivate und ihre therapeutische verwendung
DE60132937T2 (de) 2000-09-11 2009-02-12 Novartis Vaccines and Diagnostics, Inc., Emeryville Verfahren zur Herstellung von Benzimidazol-2-yl -Chinolinonderivaten
AUPR007600A0 (en) * 2000-09-13 2000-10-05 Kajlich, Anti Equipment for faster swimming pools
EP1322656B1 (de) 2000-09-26 2008-01-16 Idera Pharmaceuticals, Inc. Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
NZ525320A (en) 2000-10-18 2004-10-29 Glaxosmithkline Biolog S Combinations of immunostimulatory oligonucleotides (CpG), saponin and optionally lipopolysaccharides as potent vaccine adjuvants
GB0025577D0 (en) 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
ATE503493T1 (de) 2001-02-23 2011-04-15 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
WO2002067983A1 (en) 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
DE60238471D1 (de) 2001-03-09 2011-01-13 Id Biomedical Corp Quebec Proteosom-liposaccharid-vakzine-adjuvans
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
DE10144903A1 (de) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
YU45204A (sh) 2001-11-27 2006-08-17 Anadys Pharmaceuticals Inc. 3-BETA-D-RIBOFURANOZILTIAZOLO/4,5-d/ PIRIMIDINSKI NUKLEOZIDII NJIHOVA UPOTREBA
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
US6861410B1 (en) * 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
IL164302A0 (en) 2002-03-29 2005-12-18 Chiron Corp Substituted benzazoles and use thereof as raf kinase inhibitors
WO2003101949A2 (en) 2002-05-29 2003-12-11 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
CA2493690C (en) 2002-06-13 2011-11-08 New York University Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
JP2006501243A (ja) 2002-08-23 2006-01-12 カイロン コーポレイション グリコーゲンシンターゼキナーゼ３のピロールベースのインヒビター
WO2004060308A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
EP1594524B1 (de) 2003-01-21 2012-08-15 Novartis Vaccines and Diagnostics, Inc. Verwendung von tryptanthrin-verbindungen zur immunverstärkung
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
CN1764473A (zh) 2003-03-24 2006-04-26 英特塞尔股份公司 矾与Th1免疫应答诱导佐剂用于增强免疫应答的用途
EP1608369B1 (de) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Verwendung von organischen verbindungen zur immunpotenzierung
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
BRPI0412855B8 (pt) 2003-07-24 2022-06-28 Merial Inc formulações de vacina
RU2236257C1 (ru) 2003-09-15 2004-09-20 Косяков Константин Сергеевич Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
EP1528101A1 (de) 2003-11-03 2005-05-04 ProBioGen AG Immortalisierte Vogel-Zelllinien für die Produktion von Viren
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
EP1550458A1 (de) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergisitische liposomale Adjuvantien
CA2559371C (en) * 2004-03-09 2014-07-08 Chiron Corporation Influenza virus vaccines
CN1933862A (zh) 2004-03-23 2007-03-21 尼普洛株式会社 预充式注射器
US20050222048A1 (en) 2004-03-31 2005-10-06 The Research Foundation Of The City University Of New York Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
AU2005230708B2 (en) 2004-04-05 2009-01-15 Zoetis Services Llc Microfluidized oil-in-water emulsions and vaccine compositions
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
AU2005245943A1 (en) 2004-05-20 2005-12-01 Id Biomedical Corporation Process for the production of an influenza vaccine
CA2565500A1 (en) 2004-05-28 2005-12-15 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
EP2277595A3 (de) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Verbindungen zur Immunopotenzierung
DE102004032251B4 (de) 2004-07-03 2008-05-29 Daimler Ag Vorrichtung zur Abscheidung von Wasser und zur Ausfilterung von Verunreinigungen
CA2890962A1 (en) 2004-09-09 2006-03-16 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Decreasing potential iatrogenic risks associated with influenza vaccines
US20070292386A9 (en) 2004-12-02 2007-12-20 Campbell Robert L Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
KR101260084B1 (ko) 2004-12-23 2013-05-03 메디뮨 엘엘씨 바이러스의 증식을 위한 비종양형성성 ｍｄｃｋ 세포주
EP2295542B1 (de) 2004-12-24 2013-01-30 Abbott Biologicals B.V. Rückgewinnung von Influenza Virus
CA2603180C (en) 2005-03-23 2015-10-13 Glaxosmithkline Biologicals S.A. Influenza vaccine compositions and method for immunization against influenza disease
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
TWI397969B (zh) 2005-07-11 2013-06-01 Brooks Automation Inc 具有迅速工件定中心功能的加工裝置
US7425336B2 (en) * 2005-08-25 2008-09-16 Mevial Limited Canine influenza vaccines
US7384642B2 (en) * 2005-08-25 2008-06-10 Merial Limited Canine influenza vaccines
WO2007052059A2 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Changing th1/th2 balance in split influenza vaccines with adjuvants
WO2007052060A1 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines extemporaneously adsorbed to aluminium adjuvants
AU2007258874B2 (en) * 2006-06-15 2013-11-14 Seqirus UK Limited Adjuvant-sparing multi-dose influenza vaccination regimen
EA200970271A1 (ru) * 2006-09-11 2010-02-26 Новартис Аг Получение вакцин против вируса гриппа без использования куриных эмбрионов
AR066405A1 (es) 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa Vacuna
US8506966B2 (en) * 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
NZ600323A (en) * 2009-12-03 2013-12-20 Novartis Ag Circulation of components during microfluidization and/or homogenization emulsions

Also Published As

Publication number Publication date
NZ567981A (en) 2011-10-28
ES2792398T3 (es) 2020-11-11
FIC20240033I1 (fi) 2024-10-18
PL1945252T3 (pl) 2013-11-29
HUE051122T2 (hu) 2021-03-01
EP2368572A2 (de) 2011-09-28
US10842867B2 (en) 2020-11-24
EP2368572A3 (de) 2013-04-24
CA2628152A1 (en) 2007-05-10
EP3714900A1 (de) 2020-09-30
EP2368572B1 (de) 2020-03-04
EP1945252B1 (de) 2013-05-29
PL2368572T3 (pl) 2020-11-16
EP1945252A1 (de) 2008-07-23
DK2368572T3 (da) 2020-05-25
CA2628152C (en) 2016-02-02
AU2006310336A1 (en) 2007-05-10
US20240299537A1 (en) 2024-09-12
WO2007052055A1 (en) 2007-05-10
AU2006310336B2 (en) 2011-02-03
JP2009514838A (ja) 2009-04-09
HK1122997A1 (en) 2009-06-05
PT2368572T (pt) 2020-06-16
US20090220544A1 (en) 2009-09-03
ES2420829T3 (es) 2013-08-27

Similar Documents

Publication Publication Date Title
FR20C1043I1 (fr) Vaccins avec adjuvants dotés d'antigènes non virioniques préparés à partir de virus de la grippe cultivés dans une culture cellulaire
FR20C1046I1 (fr) Vaccins contre la grippe contenant de l'hémagglutinine et des protéines de matrice
NO2017005I1 (no) Human pappilomavirus vaksine [type 6, 11, 16, 18, 31, 33, 45, 52, 58]
EP1924280A4 (de) Impfung gegen dengue-virus-infektion
PT2121011E (pt) Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
SG2014007934A (en) Modified influenza virus for monitoring and improving vaccine efficiency
JP2006527762A5 (de)
IL198466A (en) Use of dengue fever vaccines to produce a single-value vaccine and four-value vaccine to vaccinate against dengue fever virus and vaccine kits against dengue fever containing these vaccines
WO2007052059A3 (en) Changing th1/th2 balance in split influenza vaccines with adjuvants
WO2004080403A3 (en) Influenza virus vaccine
EP2114449A4 (de) Kombinierte herpes simplex virus subunit-impfstoffe und anwendungsverfahren
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
BRPI0811499A2 (pt) Métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral.
EP1856250A4 (de) Neue lebende virus-impfstoffe
FR15C0082I2 (fr) Vaccin contre les virus hpv16 et hpv18 et au moins un autre type de hpv selectionne parmi hpv 31, 45 ou 52
EP1846028A4 (de) Transportmittel, bioaktive substanzen und virale impfstoffe
EP1841451A4 (de) Peptide zur verabreichung von schleimhautimpfstoffen
FR2922767B1 (fr) Procede de preparation d'une composition vaccinale comprenant au moins un antigene et au moins un adjuvant.
HK1121698A1 (en) Marked bovine viral diarrhea virus vaccines
ATE490782T1 (de) Chimäre vakzine-antigene gegen das klassische schweinefieber-virus
ATE437656T1 (de) Impfstoff gegen das maul- und klauensäure-virus
ATE392903T1 (de) Impfstoff gegen pferdeherpesvirus
EP2054081A4 (de) Impfstoff gegen den jc-virus
IS7775A (is) DNA bóluefni sem umritar að minnsta kosti tvö óformgerð árprótín af vörtuveiru
AU2005279590A1 (en) Vaccine composition against hepatitis C virus